Temozolomide induces the expression of the glioma Big Potassium (gBK) ion channel, while inhibiting fascin-1 expression: possible targets for glioma therapy

Expert Opinion on Therapeutic Targets

Volumn 20, Issue 10, 2016, Pages 1155-1167

  Hoa, Neil T ^a   Ge, Lisheng ^a   Martini, Filippo ^a,b   Chau, Vincent ^a   Ahluwalia, Amrita ^a   Kruse, Carol A ^c   Jadus, Martin R ^a,d  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cytolytic T lymphocytes; fascin 1; glioblastoma multiforme; glioma BK ion channel; microvilli; real time PCR; temozolomide; TMZ

Indexed keywords

BETA ACTIN; FASCIN; FASCIN 1; GLIOMA BIG POTASSIUM ION CHANNEL; GLOBULAR PROTEIN; GLYCOPROTEIN; INTERLEUKIN 6; MESSENGER RNA; POTASSIUM CHANNEL; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; ALKYLATING AGENT; CARRIER PROTEIN; DACARBAZINE; FSCN1 PROTEIN, HUMAN; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL;

ACTIN FILAMENT; ADHERENT CELL; ARTICLE; CANCER CHEMOTHERAPY; CELL POPULATION; CELL STRUCTURE; DRUG TARGETING; FLOW CYTOMETRY; GLIOMA; GLIOMA CELL; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOLECULAR WEIGHT; PROTEIN DEPLETION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GLIOBLASTOMA; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; CARRIER PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; DACARBAZINE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; GLIOMA; HUMANS; LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; MICROFILAMENT PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84978524087     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1080/14728222.2016.1208172     Document Type: Article

References (58)

1. R.Stupp, M.E.Hegi, W.P.Mason, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study:5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–466.
2. B.J.Denny, R.T.Wheelhouse, M.F.G.Stevens, et al. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry. 1994;33(31):9045–9051.
3. B.Kaina, M.Christmann, S.Naumann, et al. MGMT:Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair. 2007;6(8):1079–1099.
4. G.J.Kitange, B.L.Carlson, M.A.Schroeder, et al. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol. 2009;11(3):281–291.
5. M.E.Hegi, A.-C.Diserens, T.Gorlia, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003.
6. W.P.Roos, L.F.Batista, S.C.Naumann, et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene. 2007;26(2):186–197.
7. T.Kanzawa, I.M.Germano, T.Komata, et al. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 2004;11(4):448–457.
8. Y.Hirose, M.S.Berger, R.O.Pieper Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res. 2001;61(15):5843–5849.
9. E.A.Natelson, D.Pyatt. Temozolomide-induced myelodysplasia. Adv Hematol. 2010;2010:1–5.
10. A.B.Schwarzberg, E.H.Stover, T.Sengupta, et al. Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide. Cancer Invest. 2007;25(4):249–255.
11. Y.-W.Su, M.-C.Chang, M.-F.Chiang, et al. Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J Neurooncol. 2005;71(3):315–318.
12. M.Bauer, M.Goldstein, D.Heylmann, et al. Human monocytes undergo excessive apoptosis following temozolomide activating the ATM/ATR pathway while dendritic cells and macrophages are resistant. PLoS One. 2012;7(6):e39956.
13. C.Banissi, F.Ghiringhelli, L.Chen, et al. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother. 2009;58(10):1627–1634.
14. X.Xu, F.Stockhammer, A.Schmitt, et al. Therapeutical doses of temozolomide do not impair the function of dendritic cells and CD8+ T cells. Int J Oncol. 2012;40(3):764–772.
15. C.-H.Kim, S.-J.Woo, J.-S.Park, et al. Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma. Immunology. 2007;122(4):615–622.
16. S.De Vleeschouwer, F.Van Calenbergh, P.Demaerel, et al. Transient local response and persistent tumor control in a child with recurrent malignant glioma:treatment with combination therapy including dendritic cell therapy. Case report. J Neurosurg. 2004;100(5 Suppl Pediatrics):492–497.
17. G.Liu, Y.Akasaki, H.T.Khong, et al. Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene. 2005;24(33):5226–5234.
18. R.M.Prins, H.Soto, V.Konkankit, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011;17(6):1603–1615.
19. A.K.Weaver, X.Liu, H.Sontheimer. Role for calcium-activated potassium channels (BK) in growth control of human malignant glioma cells. J Neurosci Res. 2004;78(2):224–234.
20. C.B.Ransom, H.Sontheimer. BK channels in human glioma cells. J Neurophysiol. 2001;85(2):790–803.
21. H.Sontheimer. An unexpected role for ion channels in brain tumor metastasis. Exp Biol Med (Maywood). 2008;233(7):779–791.
22. G.Debska, A.Kicinska, J.Dobrucki, et al. Large-conductance K+ channel openers NS1619 and NS004 as inhibitors of mitochondrial function in glioma cells. Biochem Pharmacol. 2003;65(11):1827–1834.
23. X.Liu, Y.Chang, P.H.Reinhart, et al. Cloning and characterization of glioma BK, a novel BK channel isoform highly expressed in human glioma cells. J Neurosci. 2002;22(5):1840–1849.
24. L.Ge, N.T.Hoa, Z.Wilson, et al. Big Potassium (BK) ion channels in biology, disease and possible targets for cancer immunotherapy. Int Immunopharmacol. 2014;22(2):427–443.•• This article shows that BK channels have a complex interplay with intracellular components of cancer cells. In this review, the focus is on the biology of the BK channel and its important role in immune response toward cancer specifically with brain tumors.
25. L.Ge, N.T.Hoa, A.N.Cornforth, et al. Glioma big potassium channel expression in human cancers and possible T cell epitopes for their immunotherapy. J Immunol. 2012;189(5):2625–2634.•• This study shows that peptides derived from cancer-associated ion channels maybe useful targets for T cell-mediated immunotherapy.
26. N.T.Hoa, L.Ge, R.B.Tajhya, et al. Small cell lung cancer cells express the late stage gBK tumor antigen:a possible immunotarget for the terminal disease. Am J Transl Res. 2014;6(3):188–205.
27. N.Hoa, L.Ge, Y.Kuznetsov, et al. Glioma cells display complex cell surface topographies that resist the actions of cytolytic effector lymphocytes. J Immunol. 2010;185(8):4793–4803.•• The article demonstrates that glioma have a complex surface topography with numerous microvilli and filopodia with nodelike structures that play multiple roles in glioma biology, such as compartmentalization to resist physical damage, resistance to lymphocyte-mediated killing, and essential for the invasion process.
28. A.Q.Dang, N.T.Hoa, L.Ge, et al. Using REMBRANDT to paint in the details of glioma biology:applications for future immunotherapy. In:T.Lichtor, editor. Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications. InTech; 2013. p. 167–200. doi:10.5772/50198
29. G.Arismendi-Morillo, N.T.Hoa, L.Ge, et al. Mitochondrial network in glioma’s invadopodia displays an activated state both in situ and in vitro:potential functional implications. Ultrastruct Pathol. 2012;36(6):409–414.•• This paper describes two prominent structural features of the mitochondrial network present within the glioma´s invadopodia with two features (activated mitochondria and smooth ER, along with mitochondria contained within the filopodia) might provide researchers with possible targets for future therapies that can control glioma invasiveness.
30. M.Nakada, H.Nakamura, E.Ikeda, et al. Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol. 1999;154(2):417–428.
31. H.L.Fillmore, T.E.VanMeter, W.C.Broaddus. Membrane-type matrix metalloproteinases (MT-MMPs):expression and function during glioma invasion. J Neurooncol. 2001;53(2):187–202.
32. V.Thorns, G.F.Walter, C.Thorns. Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas. Anticancer Res. 2003;23(5a):3937–3944.
33. H.Zhao, M.Sokabe. Tuning the mechanosensitivity of a BK channel by changing the linker length. Cell Res. 2008;18(8):871–878.
34. M.Steinle, D.Palme, M.Misovic, et al. Ionizing radiation induces migration of glioblastoma cells by activating BK K(+) channels. Radiother Oncol. 2011;101(1):122–126.
35. J.C.Adams. Roles of fascin in cell adhesion and motility. Curr Opin Cell Biol. 2004;16(5):590–596.
36. A.Peraud, S.Mondal, C.Hawkins, et al. Expression of fascin, an actin-bundling protein, in astrocytomas of varying grades. Brain Tumor Pathol. 2003;20(2):53–58.
37. A.A.Roma, R.A.Prayson. Fascin expression in 90 patients with glioblastoma multiforme. Ann Diagn Pathol. 2005;9(6):307–311.
38. Y.Hashimoto, T.Ito, H.Inoue, et al. Prognostic significance of fascin overexpression in human esophageal squamous cell carcinoma. Clin Cancer Res. 2005;11(7):2597–2605.
39. B.J.Yoder, E.Tso, M.Skacel, et al. The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. Clin Cancer Res. 2005;11(1):186–192.
40. J.H.Hwang, C.A.Smith, B.Salhia, et al. The role of fascin in the migration and invasiveness of malignant glioma cells. Neoplasia. 2008;10(2):149–159.
41. L.M.Machesky, A.Li. Fascin:invasive filopodia promoting metastasis. Commun Integr Biol. 2010;3(3):263–270.
42. A.Li, J.C.Dawson, M.Forero-Vargas, et al. The actin-bundling protein fascin stabilizes actin in invadopodia and potentiates protrusive invasion. Curr Biol. 2010;20(4):339–345.
43. N.T.Hoa, L.Ge, K.L.Erickson, et al. Fascin-1 knock-down of human glioma cells reduces their microvilli/filopodia expression while improving their susceptibility to lymphocyte-mediated cytotoxicity. Amer J Trans Res. 2015;7(2):271–284.
44. M.L.Heidrick, W.L.Ryan. Adenosine 3’,5’-cyclic monophosphate and contact inhibition. Cancer Res. 1971;31(9):1313–1315.
45. J.G.Zhang, C.A.Kruse, L.Driggers, et al. Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy. J Neurooncol. 2008;88(1):65–76.
46. J.G.Zhang, J.Eguchi, C.A.Kruse, et al. Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin Cancer Res. 2007;13(2 Pt 1):566–575.
47. C.E.Chan, D.J.Odde. Traction dynamics of filopodia on compliant substrates. Science. 2008;322(5908):1687–1691.
48. B.G.Ricart, M.T.Yang, C.A.Hunter, et al. Measuring traction forces of motile dendritic cells on micropost arrays. Biophys J. 2011;101(11):2620–2628.
49. R.Li, G.Li, L.Deng, et al. IL-6 augments the invasiveness of U87MG human glioblastoma multiforme cells via up-regulation of MMP-2 and fascin-1. Oncol Rep. 2010;23(6):1553–1559.
50. Q.Liu, G.Li, R.Li, et al. IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines. J Neurooncol. 2010;100(2):165–176.
51. C.Happold, P.Roth, W.Wick, et al. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. J Neurochem. 2012;122(2):444–455.
52. S.Sun, T.S.Wong, X.Q.Zhang, et al. Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines. J Neurooncol. 2012;107(1):89–100.
53. G.J.Kitange, B.L.Carlson, M.A.Schroeder, et al. Expression of CD74 in high grade gliomas:a potential role in temozolomide resistance. J Neurooncol. 2010;100(2):177–186.
54. D.B.Bocangel, S.Finkelstein, S.C.Schold, et al. Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res. 2002;8(8):2725–2734.
55. T.Hafting, O.Sand. Purinergic activation of BK channels in clonal kidney cells (Vero cells). Acta Physiol Scand. 2000 Oct;170(2):99–109.
56. P.W.Furlow, S.Zhang, T.D.Soong, et al. Mechanosensitive pannexin-1 channels mediate microvascular metastatic cell survival. Nat Cell Biol. 2015;17(7):943–952.
57. A.Bringmann, T.Pannicke, M.Weick, et al. Activation of P2Y receptors stimulates potassium and cation currents in acutely isolated human Müller (glial) cells. Glia. 2002;37(2):139–152.
58. C.Sedwick, B.Short. Tubulin transport pumps up cilia [biosights video]. Sedwick C, editor and producer. New York (NY):The Rockefeller University Press; 2015. MP4 video:6.5min., sound, color.